| Tahiti |
| |
| CHK Nutrition |
|
Urinary Neurotransmitter Testing |
|
with Medical Foods Discussion |
|
The FDA registered Medical Foods
of CHK were developed by |
|
medical doctors while caring for their patients in clinics. |
| |
|
What is Urinary Neurotransmitter Testing? |
|
Urinary
monoamine neurotransmitter testing IS NOT simply measuring
neurotransmitter levels to determine if they are, "high or low".
While this approach has been promoted by laboratories directed
by people with no medical license since 2002 the fact remains
there is no correlation between urinary neurotransmitter and
systemic neurotransmitters. Monoamine neurotransmitter filtered
at the glomerulous are metabolized in the kidney long before
they make it to the urine. |
|
|
Properly
performed urinary neurotransmitter testing is an evaluation of
the Organic Cation Transporters (OCT) of the proximal convoluted
renal tubule cells of the kidneys. Medical literature is clear
that the OCT of the kidneys, liver, GI tract, and brain are
"identical and homologous". As amino acid precursors of the body
come to equilibrium the effects of the amino acids are,
"identical and homologous". |
|
| |
|
Scientific Basis for |
|
Urinary Monoamine Neurotransmitter Testing |
|
The urinary
neurotransmitter testing assays of the Organic Cation Transporters
developed by Marty Hinz, MD of NeuroResearch Clinics, Inc. since 2001
has gained scientific recognition and validity in the form of major
Universities writing peer reviewed literature on the approach. |
| |
|
University of Minnesota Medical School |
|
writings on the findings of Marty Hinz, MD |
|
Published May 1, 2009 |
|
U of MN urinary neurotransmitter testing writing |
| |
|
Johns Hopkins Medical Text Book Chapter 29 |
|
Use of amino acids in the treatment of
depression |
|
By Marty Hinz, MD Published February 7, 2009 |
|
Johns Hopkins
Chapter Depression Amino Acids and Testing |
| |
|
Review of Amino Acids and Urinary
Neurotransmitter Testing |
|
by the Texas Board of Medical Practice |
|
The real acid
test of a new medical treatment is review by a state medical
board. In May of 2009 a physician in Texas was called before the
Texas State Medical Board to respond to a number of concerns.
One of the concerns of the Texas State Medical Board was
questioning the use of urinary neurotransmitter testing during
treatment with amino acids. After review by the Texas Medical
Board the case was dismissed and no action was taken. Below is a
copy of the letter submitted by Marty Hinz, MD to the Texas
Medical Board on behalf of this physician. |
|
|
Letter to the
Texas Board of Medical Practice |
| |
| |
